China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 31,586 shares, a decrease of 39.9% from the February 26th total of 52,570 shares. Based on an average daily trading volume, of 26,742 shares, the short-interest ratio is currently 1.2 days. Currently, 3.4% of the shares of the company are sold short.

Institutional Trading of China SXT Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of China SXT Pharmaceuticals during the fourth quarter worth approximately $36,000. Virtu Financial LLC boosted its stake in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in China SXT Pharmaceuticals during the third quarter worth approximately $78,000. Institutional investors own 5.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday, February 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Trading Down 2.9%

SXTC stock opened at $1.32 on Friday. China SXT Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $1,046.99. The business’s fifty day moving average price is $4.50 and its two-hundred day moving average price is $143.09.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million for the quarter.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.